Causaly Secures $60 Million Series B Funding Round
Causaly, a pioneering company based in London, UK, and Athens, Greece, has successfully secured a remarkable $60 million in Series B funding. This latest investment elevates the total funding amount to an impressive $93 million. The funding round was spearheaded by ICONIQ Growth, which is known for supporting innovative technology firms. Additional participation came from a variety of well-respected entities, including Index Ventures, Marathon Venture Capital, the European Bank for Reconstruction and Development (EBRD), Pentech Ventures, and Visionaries Club. Notably, strategic investors such as Alex Gorsky, the former Chairman and CEO of Johnson & Johnson, and Olivier Pomel, the CEO and Co-Founder of Datadog, also contributed to the round, signaling strong confidence in Causaly's potential.
In conjunction with the funding, Caroline Xie, a general partner at ICONIQ Growth, has joined Causaly’s board of directors.
This addition is expected to provide valuable insights and guidance as the company seeks to leverage the newly acquired funds to enhance its product offerings and expand its commercial relationships within the industry. Founded in 2018, Causaly is led by CEO Yiannis Kiachopoulos and CTO Artur Saudabayev. The firm specializes in delivering an AI-driven platform tailored for modern Life Sciences research organizations, equipping them with the tools necessary to find, analyze, and utilize data effectively in pivotal decision-making processes related to drug discovery and development.
The innovative platform created by Causaly plays a crucial role in modernizing complex research workflows. By supporting a vast array of knowledge-driven processes, it accelerates the transition from initial laboratory research to the clinical launch of new therapies. Utilizing a hybrid methodology that fuses a comprehensive knowledge graph with advancements in generative AI, Causaly empowers researchers to engage in thorough and unbiased scientific exploration. The technology is witnessing widespread adoption across various research teams, influencing workflows from target identification to biomarker discovery. Esteemed clientele includes notable organizations such as Gilead, Novo Nordisk, Regeneron, the Food and Drug Administration, and the National Institute of Environmental Health Sciences, all of which highlight Causaly's transformative impact on the biomedical research landscape.
They've invested in Causaly
Get to know these Healthtech investors
| Investor | Sector | Stage | Activity | Team | Connect |
|---|---|---|---|---|---|
 ICONIQ Capital | 4 investments investments | more info | |||
 Index Ventures | 16 investments investments | 11 contacts contacts | |||
 Marathon Venture Capital | 3 investments investments | 3 contacts contacts | |||
 European Bank for Reconstruction and Development (EBRD) | 1 investment investment | more info | |||
 Pentech | 2 investments investments | 4 contacts contacts |
Click here for a full list of 7,589+ startup investors in the UK